STOCK TITAN
  1. Home
  2. Sec-filings
  3. PRME
  4. [8-K] Prime Medicine, Inc. Reports Material Event

Prime Medicine (NASDAQ: PRME) cleared of breach in Beam arbitration ruling

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Prime Medicine, Inc. reported that an arbitration tribunal issued a final award resolving its dispute with Beam Therapeutics over their 2019 Collaboration and License Agreement. The tribunal declared that PM647, Prime Medicine’s development candidate for treating Alpha-1 Antitrypsin Deficiency, falls within Prime Medicine’s contractual field and that the company did not breach the agreement. As a result, the tribunal denied Beam’s requests for damages and injunctive relief based on its breach allegations. The tribunal also denied the remaining claims brought by both Beam and Prime Medicine.

Positive

  • Arbitration outcome clears breach allegation: The tribunal declared that PM647 is within Prime Medicine’s contractual field and that the company did not breach the 2019 collaboration agreement with Beam Therapeutics, removing Beam’s core contractual challenge.
  • No damages or injunctive relief awarded: The tribunal denied Beam’s requests for damages and injunctive relief based on its breach assertion, so Prime Medicine faces no such remedies from this arbitration.

Negative

  • None.

Insights

Arbitration removes claimed breach, damages and injunction risk.

The final arbitration award confirms that PM647 is within Prime Medicine’s contractual field under the 2019 collaboration with Beam Therapeutics. The tribunal concluded Prime Medicine did not breach the agreement, directly addressing Beam’s core allegation.

Because of this finding, Beam’s requests for damages and injunctive relief were denied, meaning no payments or court-like restrictions arise from Beam’s breach claims. The tribunal also rejected all other claims from both parties, fully resolving the arbitration on the terms described.

Item 8.01 Other Events Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Final award date July 6, 2026 Date tribunal issued the final arbitration award
Agreement year 2019 Year of Collaboration and License Agreement with Beam
Final Award regulatory
"received a final award (the "Final Award") from the arbitration tribunal"
arbitration tribunal regulatory
"received a final award (the "Final Award") from the arbitration tribunal (the "Tribunal")"
Collaboration and License Agreement financial
"regarding the parties' 2019 Collaboration and License Agreement (the "Agreement")"
A collaboration and license agreement is a legal contract where two or more parties agree to work together on developing or selling a product or technology while granting one another specific rights to use patents, know‑how, or other intellectual property. For investors, it matters because such deals can bring upfront payments, milestone or royalty income, and shared development costs and risks—like two neighbors pooling tools to renovate a house, which can speed progress and change future revenue potential.
Alpha-1 Antitrypsin Deficiency medical
"PM647, the Company's development candidate for the treatment of Alpha-1 Antitrypsin Deficiency ("AATD")"
A genetic condition in which the body makes too little of a protective protein called alpha‑1 antitrypsin, leaving lungs and sometimes the liver vulnerable to damage; imagine a car missing some brake pads so wear and tear accelerates. It matters to investors because the condition defines a specific patient population, shapes demand for diagnostics and therapies, and concentrates regulatory, clinical trial and reimbursement risks and opportunities for companies developing treatments.
injunctive relief regulatory
"denied Beam's requests for damages and injunctive relief based on Beam's assertion"
A court-ordered instruction requiring a person or company to do or stop doing a specific action to prevent harm or preserve a situation. For investors, injunctive relief can immediately alter a business’s operations, block sales or product use, or preserve assets—like a referee pausing play to prevent unfair advantage—so it can swiftly affect revenue, legal exposure and share value while longer legal battles continue.

FAQ

What did the arbitration tribunal decide for Prime Medicine (PRME)?
The tribunal issued a final award declaring Prime Medicine did not breach its 2019 Collaboration and License Agreement with Beam. It found PM647 is within Prime Medicine’s contractual field and denied Beam’s requests for damages and injunctive relief based on alleged breach.

How does the arbitration ruling affect PM647 for Prime Medicine (PRME)?
The tribunal determined PM647, Prime Medicine’s development candidate for Alpha-1 Antitrypsin Deficiency, falls within the company’s contractual field under the 2019 agreement with Beam. This supports Prime Medicine’s rights to PM647 under that collaboration framework.

Were any damages awarded against Prime Medicine (PRME) in the Beam dispute?
No, the arbitration tribunal denied Beam Therapeutics’ requests for damages. Those requests were based on Beam’s assertion that Prime Medicine breached the 2019 Collaboration and License Agreement, but the tribunal concluded that no breach occurred and rejected the damages claim.

Did the arbitration tribunal grant injunctive relief against Prime Medicine (PRME)?
No, the tribunal denied Beam’s requests for injunctive relief. Beam had sought this relief in connection with its claim that Prime Medicine breached the collaboration agreement, but the final award found no breach and therefore rejected those injunctive requests.

What happened to the remaining claims between Prime Medicine (PRME) and Beam?
The arbitration tribunal denied the remaining claims brought by both Prime Medicine and Beam. This means all claims presented in the binding arbitration, beyond Beam’s main breach and damages assertions, were rejected in the final award described in the report.

Which agreement between Prime Medicine (PRME) and Beam was in dispute?
The dispute concerned the parties’ 2019 Collaboration and License Agreement. The arbitration focused on whether PM647 fell within Prime Medicine’s contractual field under that agreement and whether Prime Medicine had breached any of its terms, which the tribunal ultimately rejected.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Understanding 8-K Material Events →
0001894562false00018945622026-07-062026-07-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________________
FORM 8-K
___________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

July 6, 2026
Date of Report (date of earliest event reported)
___________________________________
Prime Medicine, Inc.
(Exact name of registrant as specified in its charter)
___________________________________

Delaware
(State or other jurisdiction of
incorporation)
001-41536
(Commission File Number)
84-3097762
(I.R.S. Employer Identification No.)
60 First Street
Cambridge, MA 02141
(Address of principal executive offices and zip code)
(617) 465-0013
(Registrant's telephone number, including area code)
___________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol
Name of each exchange on which registered
Common stock, par value $.00001 per share
PRME
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§250.12b-2 of this chapter).
Emerging growth company    ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01 Other Events
On July 6, 2026, Prime Medicine, Inc. (the "Company") received a final award (the "Final Award") from the arbitration tribunal (the "Tribunal") in the Company's binding arbitration proceedings with Beam Therapeutics, Inc. ("Beam") regarding the parties' 2019 Collaboration and License Agreement (the "Agreement"). In the Final Award, the Tribunal declared that PM647, the Company's development candidate for the treatment of Alpha-1 Antitrypsin Deficiency ("AATD"), is within the Company's "Field" as defined by the Agreement, and that the Company therefore did not breach the Agreement. Consequently, the Tribunal denied Beam's requests for damages and injunctive relief based on Beam's assertion that Prime breached the Agreement. The Tribunal denied the remaining claims brought by Beam and the Company.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 8, 2026
Prime Medicine, Inc.
By:
/s/ Allan Reine
Name:
Allan Reine, M.D.
Title:
Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

3 documents

Other Documents